Evidence map›Paper›PMID 42425089›Full record

ArticleStem cell reports2026

Topical vascular organoid therapy promotes microvascular regeneration and functional recovery in porcine ischemic cardiomyopathy.

John A Farag, Shin Yajima, Yujiro Kawai, Koji Kawago, Eric Pfrender, Umayr Syed, Jennifer K Lyons, Tsuyoshi Ueyama, Hiroyuki Takashima, Yuka Matsuura and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

John A FaragDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA; Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Shin YajimaDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Yujiro KawaiDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Koji KawagoDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Eric PfrenderDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Umayr SyedDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Jennifer K LyonsDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Tsuyoshi UeyamaDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Hiroyuki TakashimaDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Yuka MatsuuraDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Gentaro IkedaStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Yu LiuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Yuanjia ZhuDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Stefan EldeDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Phillip C YangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Y Joseph WooDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA; Department of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA.
Yasuhiro ShudoDepartment of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: yshudo@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic heart disease (IHD) often progresses to heart failure due to persistent microvascular dysfunction not corrected by conventional epicardial revascularization. We developed a scaffold-free vascular organoid composed of human endothelial progenitor cells (EPCs) and mesenchymal stem cell-derived smooth muscle cells (SMCs) and evaluated its therapeutic potential in a porcine IHD model. Fourteen days after ischemia induction, bilayer EPC-SMC organoids were transplanted onto the left ventricular surface, and animals were followed for four weeks. Cardiac MRI demonstrated the preservation of left ventricular ejection fraction and modest improvement in regional function compared with controls. Histological and immunohistochemical analyses revealed the migration of transplanted cells into host myocardium, increased vascular density, and enhanced vessel maturation, while gene expression profiling showed the upregulation of angiogenesis-related genes. These findings demonstrate that scaffold-free EPC-SMC vascular organoids can engraft, promote microvascular remodeling, and preserve cardiac function after ischemic injury.

Indexed as

CardiomyopathiesMicrovesselsMyocardial IschemiaOrganoidsRegenerationAnimalsDisease Models, AnimalEndothelial Progenitor CellsHumansMesenchymal Stem CellsMyocardiumMyocytes, Smooth MuscleNeovascularization, PhysiologicRecovery of FunctionSwineangiogenesisischemic heart diseasereperfusion injurysmooth muscle cellvascular organoid

Identifiers

PMID42425089
PMCPMC13385428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.